SciELO - Scientific Electronic Library Online

vol.20 issue1Outcomes of patients enrolled in an antiretroviral adherence club with recent viral suppression after experiencing elevated viral loadsPeripartum HIV infection in very low birth weight infants fed 'raw' mother's own milk author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand



Related links

  • On index processCited by Google
  • On index processSimilars in Google


Southern African Journal of HIV Medicine

On-line version ISSN 2078-6751
Print version ISSN 1608-9693


MOORHOUSE, Michelle A.  and  COHEN, Karen. The role of rilpivirine in Southern Africa. South. Afr. j. HIV med. (Online) [online]. 2019, vol.20, n.1, pp.1-7. ISSN 2078-6751.

Rilpivirine, a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), is included as an option in first-line antiretroviral therapy (ART) for antiretroviral-naïve individuals in treatment guidelines in high-income countries, including the United States and many European countries. Rilpivirine is available in a single-tablet fixed-dose combination, has a favourable tolerability profile and is of relatively low cost. However, rilpivirine has reduced efficacy in patients commencing ART at high viral loads. Therefore, baseline viral load testing is required before commencing rilpivirine, and it is not recommended for patients commencing therapy with a viral load greater than 100 000 copies/mL. Rilpivirine is not included in the treatment regimens recommended by the World Health Organization (WHO), which form the basis of treatment guidelines in many lower- and middle-income countries. Some patients commencing standard first-line regimens experience treatment-limiting toxicity. A low-cost rilpivirine-containing fixed-dose combination would potentially be a useful addition to treatment options available in South Africa and other countries in the region, for patients who do not tolerate standard first-line ART. In this article, we explore the utility of rilpivirine as an option in ART in South Africa and the region in the context of current public-sector regimens. We consider what role rilpivirine might play if first-line therapy moves to a dolutegravir-based regimen, as has already happened in some lower- and middle-income countries, including Botswana, Kenya and Brazil. Finally, we describe emerging evidence for rilpivirine in the prevention of HIV transmission.

Keywords : HIV; Rilpivirine; Antiretrovirals; Non-nucleoside reverse transcriptase inhibitor; Southern Africa.

        · text in English     · English ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License